News
NVAX
--
0.00%
--
Factbox-Latest on the worldwide spread of the coronavirus
A panel of expert outside advisers to the U.S. Food and Drug Administration voted against approving COVID-19 booster shots for Americans, but may vote on a narrower approval for older adults later on Friday.
Reuters · 2d ago
Novavax Sees Prevent-19 Phase 3 Trial Participants Considered Fully Vaccinated, In Compliance With Mandated Vaccination Policies
-Reuters
Reuters · 2d ago
Factbox - Latest on the worldwide spread of the coronavirus
The British government will on Friday consider easing England's COVID-19 rules for international travel, a late-season boost for airlines, holiday and tourism companies which say they will not survive another winter of onerous rules and red tape.
Reuters · 2d ago
Novavax Joins Oxford University's Study Comparing Mixed COVID-19 Vaccine Regimen in Adolescents
MT Newswires · 3d ago
Novavax Inc (NVAX) EVP, Chief Legal Officer John A Herrmann Iii Sold $1.1 million of Shares
GuruFocus News · 3d ago
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded Phase 2 clinical trial called ...
PR Newswire - PRF · 3d ago
British study to test mixed COVID-19 vaccine dose schedules in children
reuters.com · 3d ago
With the European Union Buying Doses, Novavax Has Plenty of Upside Left
Investor Place · 3d ago
Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet
Zacks.com · 3d ago
Direxion plans to launch mRNA ETF to focus on technology behind COVID-19 vaccines
Direxion is planning to launch the Direxion mRNA ETF to offer investors exposure to messenger RNA technology, the cutting-edge research area that served as the basis for most COVID-19 vaccines.
Seekingalpha · 3d ago
Is Novavax (NASDAQ:NVAX) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 3d ago
Is Novavax Stock A Buy After Planning To Combine Its Covid, Flu Shots?
Is NVAX stock a buy or a sell after announcing plans to test its Covid and seasonal flu shots in one vaccine? Is Novavax stock a buy?
Investor's Business Daily · 4d ago
Novavax Inc (NVAX) EVP, CCO and CBO John Trizzino Sold $3.5 million of Shares
GuruFocus News · 4d ago
Novavax (NVAX) Gains As Market Dips: What You Should Know
Zacks.com · 5d ago
Novavax Has More Room to Run as the Vaccination Push Carries On
Investor Place · 5d ago
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients - Financial News Media
Palm Beach, FL - September 14, 2021 – FinancialNewsMedia.com News Commentary – All across the globe, innumerable scientists are looking to beat COVID-19... the two main paths are to find better vaccines and to utilize better treatments. As with most viruse...
MENAFN · 5d ago
Webull provides a variety of real-time NVAX stock news. You can receive the latest news about Novavax through multiple platforms. This information may help you make smarter investment decisions.
About NVAX
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).